NASDAQ:NCNA

NuCana Q1 2025 Earnings Results & Report

NuCana logo
$0.88 +0.02 (+1.96%)
Closing price 03:55 PM Eastern
Extended Trading
$0.87 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NuCana missed analyst earnings expectations in its Q1 2025 results, released June 2, 2025. The company reported EPS of -$126.00 versus the -$2.5820 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

NuCana EPS Results

Actual EPS
-$126.00
Consensus EPS
-$2.5820
Beat/Miss
Missed by -$123.4180
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NuCana Q1 2025 Earnings FAQ

NuCana (NASDAQ:NCNA) reported earnings of -$126.00 per share for Q1 2025, missing the consensus estimate of -$2.5820. The report was announced on Monday, June 2, 2025.

NuCana Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
NuCana plc Sponsored ADR
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, that develops investigational medicines for cancer. Its research focuses on nucleotide analogues, a class of compounds used in some cancer treatments.

The company’s ProTide platform is designed to improve how these compounds enter cells and become active. NuCana’s development programs have included NUC-3373, an investigational fluoropyrimidine, and NUC-7738, an investigational adenosine analogue, as well as NUC-1031, an earlier candidate.

NuCana’s work is centered on developing and evaluating potential cancer therapies; its drug candidates are investigational and have not been established as approved treatments.

View NuCana Profile